DHRDanaher Corporation
$219.87+1.11%
0.4% To PivotData as of Oct 9, 2026
Loading theme radar
Obesity and GLP-1 Stocks
Commercial GLP-1 leaders, next-generation metabolic drug developers, diabetes devices, and digital health platforms.
3M Return+2.0%
YTD Return+0.1%Year to date
vs SPY (3M)-2.2%Theme minus SPY
Total Stocks22Curated universe
Setup Distribution
Breaking Out0
Near Pivot3
Forming2
Total Setups5
Theme vs SPY (3M)
GLP-1 Stocks+1.3%
SPY+3.6%
Top Setups in GLP-1 Stocks(3 of 5 shown)
Open theme screener
PFEPfizer Inc.
$28.27+1.62%
2.3% To PivotData as of Oct 9, 2026
MRKMerck & Co., Inc.
$145.57+2.24%
5.2% To PivotData as of Oct 9, 2026
Unlock all 5 setups in GLP-1 Stocks
See every active, near-pivot, and forming setup with full charts, advanced filtering, historical performance, alerts, and much more.
All setups and full details Advanced filters & sorting Real-time alerts & notifications
After your 7-day trial: $10/month billed annually ($120/year), or $15/month. No credit card required. No charge unless you upgrade.
Today in GLP-1 Stocks
Data as of Oct 12, 2026Theme Performance
| Today (1D) | +1.93% |
| 5D | -2.14% |
| 1M | +2.11% |
| 3M | +2.04% |
| YTD | +0.06% |
| 1Y | +37.82% |
| vs SPY Benchmark | |
| Today (1D) | +1.33% |
| 1M | -0.22% |
| YTD | -14.12% |
Top Movers
Theme News
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
zacks.com · 3d ago$ABT
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
zacks.com · 3d ago$ABT
Setup coverage is limited to 3 free previews. Rows marked Pro are outside this preview. Unlock Pro to see setup coverage across all 22 stocks.
| # | Ticker | Company | Price | % Change | RS Rating | Market Cap | Setups | Status | Watch |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Merck & Co., Inc. | $145.60 | +2.25% | 84 | $359.61B | (1) | Forming | ||
| 2 | Pfizer Inc. | $28.28 | +1.65% | 69 | $161.18B | (1) | Near Pivot | ||
| 3 | Danaher Corporation | $219.87 | +1.11% | 75 | $154.57B | (1) | Near Pivot | ||
| 4 | Eli Lilly and Company | $1,179.27 | +0.80% | 73 | $1.11T | Pro | Pro | ||
| 5 | Thermo Fisher Scientific Inc. | $658.02 | +0.93% | 85 | $244.53B | Pro | Pro | ||
| 6 | Amgen Inc. | $414.87 | +1.82% | 78 | $223.91B | Pro | Pro | ||
| 7 | Abbott Laboratories | $99.60 | +1.13% | 50 | $173.48B | Pro | Pro | ||
| 8 | Intuitive Surgical, Inc. | $423.96 | +2.06% | 60 | $149.78B | Pro | Pro |
About GLP-1 Stocks
Research obesity, GLP-1, metabolic health, diabetes device, medtech, and healthcare platform stocks tied to weight-loss treatment demand.
22 StocksIn this theme
5 SetupsAcross 3 states
Updated DailyAfter market close (~8PM ET)
Popular Segments in this theme
Financial Data & Software Notice: VCP Scanner is an educational financial research database and stock screening software platform. VCP Scanner does not generate, recommend, or package trade decisions, buy/sell signals, or personalized investment advice. Theme baskets are quantitative metric rules, not managed funds or portfolio recommendations. See our Terms of Service and Privacy Policy.